< Back to previous page
Researcher
Daan Dierickx
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Responsible
From1 Oct 2019 → Today - Laboratory of Experimental Hematology (Division)
Member
From1 Oct 2013 → Today
Projects
1 - 10 of 15
- Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targetsFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of genetic events driving development of peripheral T cell lymphomaFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- GAINING INSIGHT IN THE MUTATIONAL PROFILE OF PT-DLBCL AND ASSESSING ITS BIOLOGICAL EFFECTS AND TRANSFORMING POTENTIALFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of rare lymphomas to uncover new biomarkers and treatment targets.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Degradation of CDK1 and HDACs as a strategy to treat T-cell malignanciesFrom1 Oct 2023 → TodayFunding: BOF - projects
- Characterization of non-canonical EZH2 transcriptional complexes to identify new therapeutic targets in peripheral T cell lymphoma.From1 Sep 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Molecular characterization of genetic events driving development of peripheral T cell lymphomaFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targetsFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Viral Oncology: molecular biology and pathogenesis of post-transplant lymphoproliferative disorder (PTLD)From13 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Extensive preclinical validation of combinations of targeted treatment for peripheral T cell lymphomaFrom10 Aug 2021 → 30 Sep 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 203
- Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma(2022)
Authors: Marlies Vanden Bempt, Koen Debackere, Sofie Demeyer, Quentin Van Thillo, Nienke Meeuws, David Nittner, Thomas Tousseyn, Jan Cools, Daan Dierickx
Pages: 2463 - 2476 - Genetic drivers of peripheral T-cell lymphomagenesis(2022)
Authors: Koen Debackere, Daan Dierickx, Gregor Verhoef, Jan Cools
- Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen(2022)
Authors: Thomas Tousseyn, Daan Dierickx
- Primary mediastinal large B-cell lymphoma is characterized by large-scale copy-neutral loss of heterozygosity(2022)
Authors: Stefania Tuveri, Koen Debackere, Lukas Marcelis, Nicolas Dierckxsens, Jonas Demeulemeester, Eftychia Dimitriadou, Daan Dierickx, Lucienne Michaux, Jan Cools, Thomas Tousseyn, et al.
Pages: 603 - 615 - CHARACTERISTICS AND OUTCOME OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID ORGAN TRANSPLANTATION(2022)
Authors: Daan Dierickx
Pages: S26 - S26 - Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment(2022)
Authors: Daan Dierickx, Martyna Pociupany
Pages: 413 - 421 - Metabolic Tumor Volume Improves Outcome Prediction in Untreated Mantle Cell Lymphoma(2022)
Authors: Vibeke Vergote, Gregor Verhoef, Ann Janssens, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe Deroose
Pages: S214 - S215 - Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study.(2022)
Authors: Daan Dierickx
Pages: 359 - 359 - Demographics and treatment outcomes in patients with EBV+ PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: First analyses.(2022)
Authors: Daan Dierickx
- Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients(2022)
Authors: Daan Dierickx
Pages: 885 - 892